Research paper

Development and validation of the HNC-LL score for predicting the severity of coronavirus disease 2019

Lu-shan Xiao,1, Wen-Feng Zhang,1, Meng-chun Gong,1, Yan-pei Zhang,1, Li-ya Liu,1,2,*, Hong-bo Zhu,2,*, Chen-yi Hu,2, Pei Kang,2, Li Liu,2,*, Hong Zhu,2,*

* These authors contributed equally to this work.
1 These authors contributed equally to this work.

Keywords: COVID-19; SARS-COV-2; Severity; Prediction; HNC-LL

ABSTRACT

Background: Information regarding risk factors associated with severe coronavirus disease (COVID-19) is limited. This study aimed to develop a model for predicting COVID-19 severity.

Methods: Overall, 690 patients with confirmed COVID-19 were recruited between 1 January and 18 March 2020 from hospitals in Honghu and Nanchang; finally, 442 patients were assessed. Data were categorised into the training and test sets to develop and validate the model, respectively.

Findings: A predictive HNC-LL (Hypertension, Neutrophil count, C-reactive protein, Lymphocyte count, Lactate dehydrogenase) score was established using multivariate logistic regression analysis. The HNC-LL score accurately predicted disease severity in the Honghu training cohort (area under the curve [AUC]=0.861, 95% confidence interval [CI]: 0.800–0.922; P<0.001); Honghu internal validation cohort (AUC=0.871, 95% CI: 0.769–0.972; P<0.001); and Nanchang external validation cohort (AUC=0.826, 95% CI: 0.746–0.907; P<0.001) and outperformed other models, including CURB-65 (confusion, uraemia, respiratory rate, BP, age >65 years) score model, MulBSTA (multilobular infiltration, hypo-lymphocytosis, bacterial coinfection, smoking history, hypertension, and age) score model, and neutrophil-to-lymphocyte ratio model. The clinical significance of HNC-LL in accurately predicting the risk of future development of severe COVID-19 was confirmed.

Interpretation: We developed an accurate tool for predicting disease severity among COVID-19 patients. This model can potentially be used to identify patients at risks of developing severe disease in the early stage and therefore guide treatment decisions.

Funding: This work was supported by the National Nature Science Foundation of China (grant no. 81972897) and Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (2015). © 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. Introduction

Coronavirus disease (COVID-19) is a communicable disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first outbreak was reported in Wuhan, China in December 2019, and it was declared a pandemic on 11 March 2020 by the World Health Organization [1]. Measures aimed at improving patient care, increasing the efficiency of resource use, and decreasing the mortality risk are urgently needed.

According to the reported data, the overall mortality rate was 2.3%, and no deaths were reported among non-severe cases [2]. An estimated 19% of patients with SARS-CoV-2 infection developed severe disease [2]. Furthermore, 61.5% of patients with the severe disease died within 28 days of admission [3]. In addition, treatment of a large number of patients with severe COVID-19 constitutes a huge strain on medical resources. Therefore, reducing the number of patients with severe COVID-19 would contribute to decreasing the associated mortality and the burden on medical resources. Although symptomatic and supportive therapies are the mainstays of treatment, these have limited efficacy since approximately 50% of patients do not attain significant clinical and imaging remission after 10 days in the hospital [4]. Therefore, early identification and triaging of patients with potential severe COVID-19 and a high risk of mortality...
Research in context

Evidence before this study

Articles probing into risk factors of severe coronavirus disease (COVID-19) and early identification of COVID-19 patients with a high risk of disease progression were searched on PubMed on 25 May 2020 using the search terms (“SARS-Cov-2” OR “novel coronavirus” OR “COVID-19”) AND (“progression” OR “deterioration” OR “severe disease”) AND (“prediction” OR “predict” OR “early identification”) without time or language restrictions. A limited number of reports have identified age, Sequential Organ Failure Assessment score, D-dimer level, coagulation dysfunction, and high neutrophil count as risk factors for severe COVID-19. However, their application in predicting disease severity has not been completely delineated. One study proposed a clinical risk score, including 10 parameters, to predict critical-type COVID-19. However, concise and effective clinical models to predict disease progression with respect to severe COVID-19 (including severe-type and critical-type) have not been completely investigated and thus deserves intensive research.

Added value of this study

In this retrospective multicohort study, the clinical characteristics of 442 hospitalised COVID-19 patients were comprehensively assessed. A predictive model (named the HNC-LL [hypertension, neutrophil count, C-reactive protein, lymphocyte count, lactate dehydrogenase] score) was developed and validated to enable early and accurate identification of COVID-19 patients at a high risk of severe disease. Compared with the CURB-65 score model, MuLBSTA score model, and neutrophil-to-lymphocyte ratio model, the HNC-LL score performed better in predicting COVID-19 severity. More importantly, the clinical significance of the HNC-LL score in accurately predicting the risk of future development of severe COVID-19 was confirmed in subgroup analyses.

Implications of all the available evidence

There is a need to pay particular attention to the neutrophil count, lymphocyte count, lactate dehydrogenase level, hypertension, and C-reactive protein level when COVID-19 patients are admitted to the hospital. Risk assessment based on the HNC-LL score is recommended for all COVID-19 patients on admission. For those mild- and moderate-type (non-severe) patients who are classified as high-risk based on the HNC-LL score, active treatment and close monitoring, with the intensity higher than routine management for non-severe patients, should be provided, so as to prevent disease progression. Patients will benefit greatly from early identification and intervention. Therefore, in the present study, we developed a COVID-19-specific predictive HNC-LL (Hypertension, Neutrophil count, C-reactive protein, Lymphocyte count, and Lactate dehydrogenase) score that could accurately identify patients with a high risk of severe disease from this specific patient subgroup in the early stage.

2. Materials and methods

2.1. Patient cohort and study design

Data of a total of 690 patients with confirmed COVID-19 were retrospectively collected between 1 January 2020 and 18 March 2020 from hospitals in Honghu and Nanchang. Overall, 574 patients in Honghu were enrolled from the People’s Hospital of Honghu and 116 patients in Nanchang were recruited from the First Affiliated Hospital of Nanchang University. All patients included in this study tested positive for SARS-CoV-2 nucleic acid and met the diagnostic criteria according to the guideline. A flowchart regarding the selection of the study participants for the training and validation cohorts is shown in Fig. 1. The protocol of this retrospective study was approved by the medical ethics committee of Nanfang Hospital of Southern Medical University and the institutional ethics review boards of participating hospitals. Written informed consent was obtained from all participants.

2.2. Definition

The spectrum of the severity of COVID-19 ranges from mild to critical cases according to some recently reported literature and the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) [7,9-12]. Patients with mild disease refer to those with mild clinical manifestations and no sign of pneumonia on imaging. Patients with moderate disease refer to those with fever and respiratory symptoms with radiological features of pneumonia. Patients with severe disease refer to those who meet any of the following criteria: respiratory distress (respiratory rate > 30 breaths/ min), oxygen saturation < 93% at rest, arterial partial pressure of oxygen/fraction of inspired oxygen < 300 mmHg, and > 50% obvious lesion progression on chest imaging within 24–48 h. People with critical disease refer to those who meet any of the following criteria: respiratory failure and requiring mechanical ventilation, shock, and other forms of organ failure that require intensive care. In the present study, all patients were diagnosed and classified based on the aforementioned definition. Patients with mild and moderate pneumonia were included in the non-severe group, while those with severe and critical disease on admission and those who had mild and moderate pneumonia on admission but developed severe disease after admission were included in the severe group.

Using the above definition of severity as a foundation, severe illness-free survival was defined as the time from admission to disease progression to a severe state.

2.3. Data collection and outcome evaluation

Clinical electronic medical records, laboratory findings, nursing records, and radiological reports for all patients with confirmed COVID-19 were reviewed. Detailed admission data, including demographic information, comorbidities, signs and symptoms, laboratory test results, and imaging reports, of each patient were collected. After admission, treatment, disease severity, outcomes, and length of stay in hospital were also recorded. Two researchers independently reviewed the electronic medical records manually and recorded the disease severity on admission, daily assessment of disease severity afterwards, progression from non-severe to severe disease, and date of progression.
The clinical data will be made available to others on reasonable request after publication. A proposal along with a detailed description of the study objectives will be needed to evaluate the reasonability of requests. After approval from the corresponding authors, the First Affiliated Hospital of Nanchang University, and the People's Hospital of Honghu, de-identified patient data will be provided.

2.4. Statistical analysis

Continuous variables are presented as medians and interquartile ranges. Categorical variables are presented as frequencies and proportion. The comparison between the non-severe and severe groups were performed using the Mann–Whitney U test, Pearson's chi-squared test, or Fisher's exact test, as appropriate. To explore the risk factors associated with severity, univariable and multivariable logistic regression models were used. In the univariate logistic regression analyses, variables with \( P < 0.05 \) were regarded as potential risk factors and included in the multivariate regression analysis with a backward elimination procedure (likelihood ratio test and elimination if \( P > 0.1 \)).

To assign patients into different cohorts, for 332 hospitalised patients in Honghu, simple random sampling in a ratio of 7:3 was performed using the “Select Cases” function in SPSS version 25.0 (IBM Corp., Armonk, New York, USA) under the parameter of “Random sample of cases”. The training cohort comprised 231 patients, and the internal validation cohort comprised 101 patients. In addition, 110 hospitalised patients from Nanchang were included as a testing cohort and further assessed as an external validation cohort.

Receiver operating characteristic (ROC) curve analysis and the Hosmer–Lemeshow test were performed to assess the discrimination and calibration of the model. The area under the ROC curve (AUC) was compared using DeLong's test. The cut-off value of the HNC-LL score was selected based on the maximum value of the Youden index. Net reclassification improvement analysis was also adopted to evaluate improvement to risk prediction.

Survival analysis was performed in the subgroup of patients who were classified as having non-severe disease on admission. The endpoint in this subgroup was defined as disease progression to a severe state after admission. The survival curves of the low and high risk groups were compared using the log-rank test, and hazard ratios (HRs) were calculated using the Cox proportional hazards model.

Statistical analyses and plots were performed using SPSS version 25.0 and R version 3.5.2 (The R Development Core Team, Vienna, Austria). The \texttt{pROC} package was used to plot the ROC curves and calculate the AUC. The \texttt{survminer} package was used to plot the severe illness-free survival curves. All statistical tests were two-sided, and analysis items with \( P \) values \( < 0.05 \) were considered statistically significant.

3. Results

3.1. Patient characteristics and clinical differences between patients with severe and non-severe COVID-19

A total of 690 patients with confirmed COVID-19 from hospitals in Honghu and Nanchang were enrolled. According to the inclusion and exclusion criteria, 442 patients were finally included and divided into three cohorts (Fig. 1). The demographic and baseline clinical characteristics of the patients in the Honghu and Nanchang cohorts are shown in Table S1. The proportions of men were 47.0%, 60.0%, and 50.2% and the proportions of patients older than 60 years were 27.4%, 17.3%, and 24.9%, in the Honghu, Nanchang, and entire cohorts, respectively. Common comorbidities included hypertension and diabetes mellitus. Relevant signs and symptoms included bacterial coinfection, cough, and fever. In total, 96.4%, 100%, and 97.3% of patients were discharged from the hospital and 3.6%, 0.0%, and 2.7% of the patients died in the Honghu, Nanchang, and entire cohorts, respectively.

Overall, there were 339 and 103 patients in the non-severe and severe groups, respectively. Patients in the severe group were older, had lower lymphocyte counts, higher neutrophil counts, lower albumin levels, and higher urea nitrogen, lactate dehydrogenase (LDH), and C-reactive protein (CRP) levels than those in the non-severe group. The differences were significant in all three cohorts. In terms of comorbidities and pneumonia-related signs and symptoms, the
proportions of patients with hypertension and bacterial coinfection were significantly higher in the severe group than in the non-severe group (Tables 1 and S2).

### 3.2. Development of the HNC-LL score for the prediction of disease severity

To effectively identify patients with potentially severe disease, a clinical characteristic-based predictive model was developed. Univariate logistic regression analysis revealed significant predictors (Table 2). The multivariate logistic regression analysis identified neutrophil count (odds ratio [OR] = 2.82, 95% confidence interval [CI]: 1.01–7.88; \( P = 0.049 \)), lymphocyte count (OR = 0.29, 95% CI: 0.12–0.69; \( P = 0.005 \)), CRP level (OR = 4.13, 95% CI: 4.13–10.32; \( P = 0.002 \)), LDH level (OR = 2.90, 95% CI: 1.26–6.68; \( P = 0.012 \)), and hypertension (OR = 2.64, 95% CI: 1.00–6.95; \( P = 0.050 \)) as independent risk factors for disease severity, and the model was built using these five variables (Table 2). The HNC-LL score was calculated for each patient using a formula derived from values of these five clinical variables weighted by their regression coefficients, as follows:

\[
\text{HNC-LL score} = 1.035 \times \text{neutrophil count (1: } \geq 6.3 \times 10^9/\text{L}; 0: < 6.3 \times 10^9/\text{L}) - 1.237 \times \text{lymphocyte count (1: } \geq 1.1 \times 10^9/\text{L}; 0: < 1.1 \times 10^9/\text{L}) + 1.419 \times \text{CRP level (1: } \geq 10 \text{ mg/L}; 0: < 10 \text{ mg/L}) + 1.066 \times \text{LDH (1: } \geq 245 \text{ U/L}; 0: < 245 \text{ U/L}) + 0.969 \times \text{hypertension (1: with; 0: without}) - 2.425
\]

The HNC-LL score had a P value of 0.882 in the Hosmer–Lemeshow test. According to the ROC analysis, the HNC-LL score performed exceptionally in categorizing patients into the severe and non-severe groups (AUC = 0.861, 95% CI: 0.800–0.922; \( P < 0.001 \)) (Fig. 2a).

Based on the largest Youden’s index, we determined an optimal cut-off value (1.508) to stratify hospitalised patients into the HNC-LLhigh (\( \geq 1.508 \)) and HNC-LLlow (\(< 1.508 \)) groups in the Honghu training cohort. The sensitivity and specificity of the model were 0.85 and 0.76, respectively. Patients in the HNC-LLhigh group were estimated to have a high risk of severe disease, while those in the HNC-LLlow group were estimated to have a low risk. The HNC-LL score classified 34 (85.0%) of 40 patients with severe COVID-19 into the HNC-LLhigh group and 6 (15.0%) of 40 patients with severe COVID-19 into the HNC-LLlow group. The estimated risk of severe disease, sensitivity, and specificity of the corresponding HNC-LL score are presented in Table S3.

### 3.3. Validation of the HNC-LL score for predicting disease severity among COVID-19 patients

To examine the generalisability of the HNC-LL score in predicting disease severity, validation and verification of the model were necessary. The HNC-LL score was validated in the Honghu internal validation cohort, in which it performed well consistently (AUC = 0.871, 95% CI: 0.769–0.972; \( P < 0.001 \)) (Fig. 2b). To further confirm the predictive efficacy, the score was validated in the Nan-chang external validation cohort, in which it performed well consistently (AUC = 0.826, 95% CI: 0.746–0.907; \( P < 0.001 \)) (Fig. 2c).

### 3.4. Comparison of different predictive models

The effectiveness and efficiency of the HNC-LL score were further assessed by comparing different predictive models. When compared with each independent risk factor within the entire cohort, the HNC-LL score demonstrated a superior predictive capability with the highest AUC, which was statistically significant (Fig. 3a). The CURB-65 (confusion, ureaemia, respiratory rate, blood pressure, age ≥65 years) score is a predictive model used to stratify patients with community-acquired pneumonia (CAP) into different management groups [13].

### Table 1

| Characteristic | Training cohort | Internal validation cohort | External validation cohort |
|---------------|-----------------|---------------------------|---------------------------|
| Demographics  |                 |                           |                           |
| Age (years)   | 29 (15.81)      | 29 (16.82)                | 25 (10.67)                |
| Male          | 64 (33.87)      | 16 (37.21)                | 9 (22.92)                 |
| Diabetes mellitus | 6 (3.14)      | 5 (12.50)                 | 4 (5.97)                  |
| Highest temperature (°C) | 36.90 (36.50 37.0) | 37.19 (36.90 37.40) | 37.20 (36.90 37.50) |
| Laboratory findings |  |  | |
| White blood cell count (× 10^9/L) | 6.20 (4.50 9.00) | 5.70 (4.00 8.50) | 4.90 (3.00 7.50) |
| Haemoglobin (g/L) | 130 (120 140) | 125 (110 140) | 115 (100 120) |
| Neutrophil count (× 10^9/L) | 7.90 (4.30 11.0) | 7.40 (4.20 10.0) | 6.90 (3.00 9.00) |
| Lymphocyte count (× 10^9/L) | 1.00 (0.60 1.50) | 0.90 (0.50 1.30) | 0.90 (0.50 1.10) |
| CRP level (mg/L) | 0.69 (0.40 1.30) | 0.63 (0.30 1.00) | 0.59 (0.30 0.90) |
| Creatinine (μmol/L) | 66.80 (50.40 73.20) | 71.20 (55.80 79.20) | 68.50 (56.20 80.10) |
| Urea (mg/dL) | 4.80 (3.70 5.60) | 5.19 (4.05 6.60) | 5.23 (4.10 6.60) |
| Albumin (g/L) | 3.60 (3.20 4.00) | 3.50 (3.10 4.00) | 3.50 (3.10 4.00) |
| C-reactive protein (mg/L) | 0.50 (0.30 0.70) | 0.50 (0.30 0.70) | 0.50 (0.30 0.70) |
| Continuous variable data are presented as median (interquartile ranges, IQR). Classified variable data are presented as median (interquartile ranges, IQR). |
The neutrophil-to-lymphocyte ratio (NLR) is reported to be an independent risk factor for patients with severe COVID-19 [14]. The MulLBSTA (multilobular infiltration, hypo-lymphocytosis, bacterial coinfection, smoking history, hypertension, and age) score is used to stratify patients with viral pneumonia into relevant risk groups [15]. The HNC-LL score was compared with these models. Only patients in the Nanchang cohort had complete clinical information that was required to calculate the CURB-65 score. The HNC-LL and CURB-65 score models were thus compared using the Nanchang cohort. The HNC-LL score outperformed the NLR and MulLBSTA score models in both the Nanchang and entire cohorts (Fig. 3b, c) and demonstrated better predictive performance than the CURB-65 score in the Nanchang cohort (Fig. 3c).

Net reclassification improvement (NRI) analysis was also adopted for comparison. Results showed that HNC-LL can provide >12% net reclassification improvement ($P = 0.019$) when compared to NLR and >17% net reclassification improvement ($P = 0.001$) (Table S4). It revealed that HNC-LL outperformed the other two models in predicting COVID-19 severity, appreciating the incremental predictive value of the HNC-LL furtherly.

### Table 2
Risk factors associated with severe illness among patients with confirmed COVID-19.

| Characteristic                              | Univariate OR (95% CI) | P value | Multivariate OR (95% CI) | P value |
|---------------------------------------------|------------------------|---------|--------------------------|---------|
| Age ($\geq$ 60 years)                       | 4.207 (2.069–8.552)    | <0.001  | 2.635 (0.999–6.945)      | 0.050   |
| Sex                                         | 0.868 (0.438–1.718)    | 0.684   |                          |         |
| Current smokers                             | 2.423 (2.014–27.388)   | 0.474   |                          |         |
| Hypertension                                | 4.117 (1.836–9.232)    | 0.001   | 2.815 (1.005–7.884)      | 0.049   |
| Diabetes mellitus                           | 4.405 (1.274–15.230)   | 0.019   |                          |         |
| Highest temperature (°C)                    | 1.697 (1.181–2.440)    | 0.004   |                          |         |
| White blood cell count, $\times 10^9$/L     | ref                    | 0.953   |                          |         |
| $<4$                                        | 0.983 (0.548–1.761)    | 0.953   |                          |         |
| $>4$                                        | 3.429 (1.616–7.276)    | 0.043   |                          |         |
| Lymphocyte count ($<1.1 \times 10^9$/L)    | 0.136 (0.064–0.286)    | 0.002   | 0.290 (0.123–0.686)      | 0.005   |
| Neutrophil count ($>6.3 \times 10^9$/L)    | 3.882 (1.652–9.122)    | 0.002   | 2.815 (1.005–7.884)      | 0.049   |
| eosinophil count, $\times 10^9$/L            | 0.155 (0.011–2.128)    | 0.163   |                          |         |
| Hemoglobin, g/dL                            | 0.996 (0.977–1.015)    | 0.671   |                          |         |
| Platelet count ($<150 \times 10^9$/L)       | 0.291 (0.126–0.675)    | 0.004   |                          |         |
| Albumin ($<34$ g/L)                         | 0.128 (0.056–0.291)    | <0.001  |                          |         |
| Total bilirubin                             | 1.036 (0.991–1.083)    | 0.121   |                          |         |
| Alanine aminotransferase (>40 U/L)          | 0.395 (0.218–1.622)    | 0.310   |                          |         |
| Prothrombin time ($>16$ s)                  | 2.423 (2.014–27.388)   | 0.474   |                          |         |
| Gamma-glutamyl transferase, U/L             | 1.000 (0.988–1.002)    | 0.974   |                          |         |
| Direct bilirubin, $\mu$mol/L                | 1.094 (1.004–1.193)    | 0.041   |                          |         |
| Lactate dehydrogenase (>245 U/L)            | 5.568 (2.701–11.478)   | <0.001  | 2.903 (1.262–6.679)      | 0.012   |
| Creatinine, $\mu$mol/L                      | 1.021 (1.009–1.033)    | <0.001  |                          |         |
| Urea nitrogen, mmol/L                       | 1.203 (1.081–1.338)    | 0.001   |                          |         |
| Creatinine kinase (>120 U/L)                | 1.498 (0.650–3.457)    | 0.343   |                          |         |
| C-reactive protein (>10 mg/L)               | 10.857 (4.816–24.477)  | <0.001  | 4.133 (1.655–10.320)     | 0.002   |
| Ground-glass opacity                        | 0.929 (0.470–1.837)    | 0.833   |                          |         |
| Local patchy shadowing                      | 0.705 (0.232–2.145)    | 0.538   |                          |         |
| Bilateral patchy shadowing                  | 1.517 (0.753–3.055)    | 0.244   |                          |         |
| Interstitial abnormalities                  | 0.791 (0.093–6.753)    | 0.83    |                          |         |
| Multi-lobular infiltration                  | 1.655 (0.743–3.690)    | 0.218   |                          |         |

OR, odds ratio; CI, confidence interval.

The neutrophil-to-lymphocyte ratio (NLR) is reported to be an independent risk factor for patients with severe COVID-19 [14]. The MulLBSTA (multilobular infiltration, hypo-lymphocytosis, bacterial coinfection, smoking history, hypertension, and age) score is used to stratify patients with viral pneumonia into relevant risk groups [15]. The HNC-LL score was compared with these models. Only patients in the Nanchang cohort had complete clinical information that was required to calculate the CURB-65 score. The HNC-LL and CURB-65 score models were thus compared using the Nanchang cohort. The HNC-LL score outperformed the NLR and MulLBSTA score models in both the Nanchang and entire cohorts (Fig. 3b, c) and demonstrated better predictive performance than the CURB-65 score in the Nanchang cohort (Fig. 3c).

Net reclassification improvement (NRI) analysis was also adopted for comparison. Results showed that HNC-LL can provide >12% net reclassification improvement ($P = 0.019$) when compared to NLR and >17% net reclassification improvement when compared to MulLBSTA ($P = 0.001$) (Table S4). It revealed that HNC-LL outperformed the other two models in predicting COVID-19 severity, appreciating the incremental predictive value of the HNC-LL furtherly.
In addition, we explored the performance of the HNC-LL score in predicting mortality. Compared with independent risk factors constituting the HNC-LL score (Figure S1a), the HNC-LL score had the highest AUC value, significant for all factors except the CRP level. When compared with the NLR and MuLBSTA score models (Figure S1b), the HNC-LL score consistently yielded the highest AUC, although the differences in AUC were not significant.

### 3.5. Clinical significance of the HNC-LL score in predicting the risk of future development of severe COVID-19 among patients

We further investigated whether the HNC-LL score could predict the risk of future development of severe COVID-19. Subgroup analysis was performed among patients diagnosed with non-severe disease on admission, including 285 and 80 patients from the Honghu and Nanchang cohorts, respectively. Moreover, 339 patients maintained their non-severe disease status and 26 progressed to severe disease after admission. The clinical characteristics of this specific patient population and the differences between the non-severe and severe groups are shown in Table S5. The five variables constituting the HNC-LL score remained significantly different between the groups even in this population. The HNC-LL score classified 259 (71.2%) and 105 (28.8%) patients into the high severe risk and low severe risk groups, respectively. The severe illness-free survival curves showed that patients in the high risk group had an unfavorable severe illness-free survival compared with those in the low risk group (HR = 6.17, 95% CI: 2.54–14.99, P < 0.001), thereby confirming the excellent discrimination ability of the HNC-LL score and suggesting that the HNC-LL score can identify patients with potentially severe COVID-19 in the early stage (Fig. 4).

Furthermore, the predictive power was compared between the HNC-LL score and other models to verify its clinical utility. ROC curve analysis revealed that the HNC-LL score outperformed independent risk factors that constituted the HNC-LL score (Fig. 5a) as well as the MuLBSTA score model and NLR model (Fig. 5b) in distinguishing patients with a high risk of disease progression with the highest AUC. Compared with the CRP level, NLR model and the MuLBSTA score, the performance of the HNC-LL score was preferable, although it yielded non-significant results. These results may indicate the clinical significance of HNC-LL from another perspective.

### 4. Discussion

In this retrospective multicohort study, the clinical characteristics of 442 hospitalised patients with COVID-19 were comprehensively assessed. A predictive model (named the HNC-LL score) was developed and validated to enable early and accurate identification of COVID-19 patients at a high risk of severe disease.

To our knowledge, this is the first study to develop a predictive model for the assessment of COVID-19 severity using a three-step approach (training, internal validation, and external validation) and to focus on a specific population of patients who presented with non-severe disease on admission but progressed to severe disease after admission. The HNC-LL score was capable of accurately stratifying COVID-19 patients diagnosed with non-severe disease on admission.
The MuLBSTA score can be used as an early predictor of mortality and compared the HNC-LL score to other recently developed score systems. This may be due to the fact that the CURB-65 score was initially designed for CAP and not for COVID-19. In addition, we compared the HNC-LL score to other recently developed score systems. The MuLBSTA score can be used as an early predictor of mortality among patients with viral pneumonia. It was proposed that the MuLBSTA score could play a role in the early prediction of mortality owing to COVID-19 [15]. The NLR model [14] was able to determine severe illness among COVID-19 patients in the early stage according to age and NLR. However, the HNC-LL score outperformed both models in predicting disease severity. One possible reason is that the HNC-LL score was derived from a multicentre and multicohort study, had undergone training and validation, and considered the heterogeneity of COVID-19 to a large extent, while the NLR model and MuLBSTA scoring model were based on single-center cohort studies. These results indicated that the HNC-LL score may be an accurate and reliable predictive tool that can be widely used. Furthermore, we compared the HNC-LL score to a recently proposed risk score (COVID-GRAM) based on a nationwide cohort to predict critical COVID-19 disease at admission by Liang et al. On one hand, the target population for the HNC-LL score was patients with severe COVID-19, including those with severe and critical disease, unlike the COVID-GRAM, which merely targeted critically ill patients. Thus, we believe that the HNC-LL and COVID-GRAM models targeted different clinical settings and yielded significantly different values. On the other hand, compared with some relatively subjective markers such as haemoptysis and dyspnea in COVID-GRAM, the five predictors assessed in the HNC-LL score (hypertension, CRP level, neutrophil count, lymphocyte count, and LDH level) were more objective. Subjective markers were highly practice based, and we did not identify markers with sufficient statistical power to be included. Objective markers were the major focus of the present study. The fewer markers assessed in the HNC-LL score also make it easier to apply in clinical practice.

We also compared HNC-LL to a recently proposed risk score [23] (COVID-GRAM) which was designed to predict critical type of COVID-19. It had to be pointed out that the two studies predict outcomes of two different target groups and are useful in different clinical settings. Our study aimed to predict disease severity, in an attempt to estimate future risk of developing of severe COVID-19 (including severe and critical type of COVID-19). Of course, we tried to evaluate the power of COVID-GRAM to predict risk of progression from non-severe type to severe type within our study population. The assessment did not pass the feasibility analysis phase for following reasons: first, hemoptysis, a predictor in COVID-GRAM, was rare within our

![Comparison of the ability to predict severe disease between the HNC-LL score and independent risk factors, MuLBSTA score, and NLR using ROC curves. Patients in the entire cohort diagnosed as non-severe on admission were included in this analysis. (a) Comparison of clinical utility between the HNC-LL score and independent risk factors. (b) Comparison of clinical utility among the HNC-LL, NLR, and MuLBSTA scores. P values were calculated using DeLong's test.](Image 85x515 to 520x738)
cohort; second, all the patients included in our study underwent an initial CT scan, and no abnormal X-ray data was available. It is a pity that we were unable to conduct this performance assessment. However, considering that the two models are useful within distinct clinical settings, we do not feel that this detracts from findings of either study. Use of a combination of the tools at different decision-making checkpoints throughout the clinical management of disease will benefit patients with COVID-19, especially since so much remains unknown regarding disease progression. Further, we would like to address the strength of the HNC-LL model in clinical practice, since factors incorporated are objective, easy to acquire, time-saving and cost-effective. Evaluation of risk is based on objective markers, which decreases variation between individuals, increases reliability and improves quality control. The ease in which factors may be determined in routine clinical practice and the low cost of the assessment will facilitate performing risk predictions in daily practice, which is extremely important for COVID-19 management as a result of the severe limitations that occur with regard to healthcare resources.

Clinical significance is of profound importance in model assessment. Early identification of patients with severe COVID-19 and early intervention by clinicians are important for saving lives. Therefore, the initial purpose of the HNC-LL score was to distinguish patients with potentially severe COVID-19 at admission. The HNC-LL score has a good discrimination power for classifying patients into the high severe risk and low severe risk groups and has significantly better predictive performance than the NLR model in this setting. The NLR model utilised age and the ratio of neutrophil count to lymphocyte count to predict severe illness. The neutrophil and lymphocyte counts were also included in the HNC-LL score. Age is a "general" factor, which involves the effect of many risk factors such as hypertension and diabetes mellitus. Age was excluded from the final model based on multivariate logistic regression analysis in this study, suggesting that it was not an independent risk predictor. The HNC-LL score includes more independent risk factors than the NLR model; thus, it may better reflect the microenvironment in patients with severe COVID-19 than the NLR model and may facilitate early and accurate identification. These results further support the clinical utility of the HNC-LL score.

The present study had several limitations. First, the number of patients included in the analysis was small, and this may limit the interpretation of our model. Additional data from different regions should be collected to expand the sample size and further validate the predictive value of the HNC-LL score. Second, some clinical indicators such as D-dimer and cytokine levels were not included owing to the unavailability of data or a large amount of missing data (>15%). The predictive effect of these indicators may be underestimated. Third, it is true that we included individuals who progressed to severe COVID-19 after admission, and also some patients who were diagnosed with severe COVID-19 upon admission, within the severe group. But the results of our subgroup analyses still firmly demonstrated the predictive power of HNC-LL in predicting disease progression. Additional comprehensive research is needed to clarify the mechanism underlying severe COVID-19, and studies with large cohorts are needed to improve this model and increase its interpretability from both biological and population perspectives.

In conclusion, we developed an effective predictive model (called the HNC-LL score) to stratify hospitalised patients into high severe risk and low severe risk groups. We suggest that when patients with COVID-19 are admitted to the hospital, it is important to pay attention to the five indicators in the HNC-LL model (neutrophil count, lymphocyte count, LDH level, CRP level, and hypertension). Risk assessment based on the HNC-LL score is recommended for all COVID-19 patients on admission. For those mild- and moderate-type (non-severe) patients who are classified as high-risk based on the HNC-LL score, active treatment and close monitoring, with the intensity higher than routine management for non-severe patients, should be provided, so as to prevent disease progression. We hope that the HNC-LL score can provide clinical guidance to doctors in controlling the pandemic.

Author contributions

Lu-shan Xiao and Wen-Feng Zhang designed the study, analysed the data, and wrote the paper. Lu-shan Xiao, Hongbo Zhu and Wen-Feng Zhang performed the literature search and constructed the figures. Mengchun Gong and Yanpei Zhang performed the data analysis and wrote the paper. Liya Chen and Pei Kang performed the statistical analyses. Li Liu and Hong Zhu designed the study, analysed the clinical data, and wrote the paper. Li Liu, Hong Zhu, and Mengchun Gong collected the data in Honghu. Wen-Feng Zhang undertook data collection in Nanchang.

Declaration of Competing Interest

The authors declare that they do not have any conflicts of interest.

Funding

This work was supported by the National Nature Science Foundation of China (grant no. 81972897) and Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (2015). The funders had no role in the study design, data collection, data analysis, interpretation, and writing of the report. This study was supported by National Key Research & Development Program of China (Project No. 2018YFC0116901). We have one co-first author, Dr. Mengchun Gong, whose research and resources used for this article has been supported by the fund listed above.

Acknowledgements

We would like to thank all study participants, their families, medical staff, and participating hospitals for their involvement and support in the present study. We thank Yao-Hong Tong, the chief of IT department, and Qing-Lang Zeng, the chief of infectious disease department at the People's Hospital of Honghu, and Yu-Lin He, a physician at the First Affiliated Hospital of Nanchang University, for their assistance in data collection in Honghu and Nanchang, respectively. We would like to thank Editage (www.editage.cn) for English language editing.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.ebiom.2020.102880.

References

[1] Sohrabi C, Alsafi Z, O'Neill N, et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg 2020;76:71–6.
[2] Wu Z, McGowan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA 2020; 323:1239–42.
[3] Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475–81.
[4] Mo P, Xing Y, Xiao Y, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis 2020 ciaa270.
[5] Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet 2020;395:1014–5.
[6] Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020:e200994.
[7] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.

[8] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033–4.

[9] National Health Commission & State Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial Version 7). Chin Med J 2020;133:E027.

[10] Wu J, Li W, Shi X, et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J Intern Med 2020. Online ahead of print. doi:10.1111/joim.13063.

[11] Chen G, Wu B, Guo W, et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J Clin Invest 2020;130:2620–9.

[12] Jin X, Lian JS, Hu JH, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020;69:1002–9.

[13] Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377–82.

[14] Liu J, Liu Y, Xiang P, et al. Neutrophil-to-lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage. medRxiv 2020. 2020. 02.10.20021584.

[15] Guo L, Wei D, Zhang X, et al. Clinical features predicting mortality risk in patients with viral pneumonia: the MulBSTA score. Front Microbiol 2019;10:2752.

[16] Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol 2020;15:700–4.

[17] Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:620–2.

[18] Sun Y, Koh V, Marinuthu K, et al. Epidemiological and clinical predictors of COVID-19. Clin Infect Dis 2020;ciaa322. Online ahead of print. doi:10.1093/cid/ciaa322.

[19] Fang L, Karakulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020;8:e21.

[20] Pepys MB, Hirschfeld GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805–12.

[21] Ling Y, Ling Y, Qian Z. Clinical analysis of risk factors for severe illness in COVID-19 patients. Chin J Infect Dis 2020;00:00023.

[22] Yan L, Zhang H-T, Goncalves J, et al. A machine learning-based model for survival prediction in patients with severe COVID-19 infection. medRxiv 2020. 2020.02.27.20028027.

[23] Liang W, Liang H, Ou L, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med 2020.